Shots: Kamada will commercialize Alvotech’s biosimilar portfolio consisting of 6 products in Israel, upon its Israeli Ministry of Health (IMOH) approval while Alvotech will remain responsible for development, manufacturing and supply of all products The collaboration leverages Kamada’s expertise and presence in the Israeli market and enables Kamada to benefit from the long-term growth potential […]Read More
Shots: Regeneron is presenting results from studies evaluating Libtayo in indications NSCLC (P-I), CSCC(P-I), HCC(P-I), BCC (P-II), R/M Cervical Cancer (P-I), Libtayo + RT+ GM-CSF for R/M HNSCC (P-I) Libtayo is a mAb targeting the immune checkpoint receptor PD-1 and was recently approved by the US FDA to treat locally advanced CSCC or mCSCC In […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
